Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Levothyroxine/Liothyronine Combination Therapy and Quality of Life: Is It All about Weight Loss?

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Previous Live Births and Induced Abortions May Precede Later Development of Graves' Hyperthyroidism

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. How Do We Improve the Impact of Iodine Deficiency Disorders Prevention in Europe and Beyond?

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Trends in Costs of Thyroid Disease Treatment in Denmark during 1995-2015

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Long-Term Outcome in Patients With Heart Failure Treated With Levothyroxine: An Observational Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Prevalence of early stages of heart failure in an elderly risk population: the Copenhagen Heart Failure Risk Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Objectives: According to one hypothesis, the popularity of levothyroxine (L-T4)/liothyronine (L-T3) combination therapy relates to weight loss. The purpose of this study was to detect a possible correlation between thyroid-related quality of life (QoL) and weight loss in hypothyroid patients switched from L-T4 monotherapy to L-T4/L-T3 combination therapy.

Methods: In an open-label cohort study, all hypothyroid patients referred to the University Hospital endocrine clinic due to persistent symptoms despite adequate L-T4 monotherapy (without other explanations for the symptoms) were switched from L-T4 monotherapy to L-T4/ L-T3 combination therapy at a ratio of approximately 17/1. At baseline and after 3 months of treatment we measured: QoL by the Thyroid Patient-Reported Outcome (ThyPRO-39) questionnaire, thyroid hormones, body weight, body composition by a DEXA-scan, and cognitive function by evaluating participants' reaction time as well as working memory by the California Computerized Assessment Package (CalCAP®). QoL was re-evaluated after 12 months.

Results: Twenty-three patients participated (91% women, median age 47 years). The ThyPRO-39 composite score decreased from a median of 54 (quartiles: 34, 74) to 15 (11, 28) after 3 months (p < 0.0001), and 20 (14, 26) after 12 months, indicating a better QoL. There was no change in body weight, and no correlations between QoL and weight. There was a slight improvement in cognitive function, whereas body composition, heart rate, and serum TSH did not change.

Conclusion: Our study on hypothyroid patients switched from L-T4 monotherapy to L-T4/L-T3 combination therapy showed a substantial improvement in QoL measured by the ThyPRO-39. This improvement could not be explained by weight loss.

Original languageEnglish
JournalEuropean Thyroid Journal
Volume7
Issue number5
Pages (from-to)243-250
Number of pages8
ISSN2235-0640
DOIs
Publication statusPublished - Oct 2018

ID: 56586791